{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.18","upperLimit":"3.38","value":"1.31"},{"groupId":"OG001","lowerLimit":"1.15","upperLimit":"3.15","value":"1.23"},{"groupId":"OG002","lowerLimit":"0.95","upperLimit":"3.29","value":"1.25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"}],"units":"Participants"}],"description":"The PFS was defined as the time from the start of study intervention until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from study intervention or received another anti-cancer therapy prior to progression.\n\nThis outcome measure was assessed only for substudy 1 Part A.","dispersionType":"Full Range","groups":[{"description":"Participants with advanced/metastatic solid tumors received AZD8853 300 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG000","title":"AZD8853 300 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 1000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG001","title":"AZD8853 1000 mg"},{"description":"Participants with advanced/metastatic solid tumors received AZD8853 3000 mg every 3 weeks until progressive disease, unacceptable toxicity, or withdrawal of consent.","id":"OG002","title":"AZD8853 3000 mg"}],"paramType":"MEDIAN","populationDescription":"Safety set included all participants who received any amount of IP.","reportingStatus":"POSTED","timeFrame":"First dose until documented disease progression or study end (1 Year)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"Months"}